KDC-MN-063 – Kodiac biolabs

Plain-language summaryIntrigue 62 / 100

Bromantane is a Russian-developed adamantane-derived adaptogen used to enhance physical and mental performance. It modulates dopamine and serotonin systems and is approved in Russia for asthenia. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

47/100

Soviet actoprotector with a genuinely unusual dual mechanism, hampered by opaque Russian-only clinical evidence

Look, bromantane is one of those compounds that sits in an awkward spot. It’s been around since the 1980s Soviet military program, it’s approved as Ladasten in Russia, and it’s been on the WADA prohibited list since 1996. None of that is new. But the mechanism is still genuinely strange enough to reward a second look, and thats what makes it worth having in the library at all.

Here’s what we find interesting: bromantane doesn’t do what you’d expect from a stimulant or an anxiolytic. Most dopaminergic compounds work by blocking reuptake (amphetamines, methylphenidate), promoting release (amphetamines again), or receptor agonism. Bromantane enhances dopamine synthesis upstream. The proposed pathway runs through increased tyrosine hydroxylase and DOPA decarboxylase expression, essentially turning up the production line rather than manipulating the distribution end. That’s a meaningfully different intervention point, and as a research probe for studying endogenous dopamine regulation it has some real appeal. The anxiolytic piece is equally odd: non-GABAergic, mechanism not fully resolved, but the clinical profile consistently distinguishes it from benzos and from sedating antihistamines.

The actoprotector concept it was built around, improving physical and cognitive performance under sustained stress without stimulant rebound or sedative blunting, maps onto real biology even if that specific Soviet framing doesnt always translate cleanly into Western pharmacology. There’s a plausible stress-resilience program you could design around bromantane as a tool.

What we don’t like: the evidence situation is uncomfortable. Substantial Russian clinical literature exists, including registration trials supporting the Ladasten approval, but the bulk of it isn’t easily accessible in English, and the methodological standards of Russian regulatory trials from the late 1990s through 2000s are hard to assess from outside that system. English-language RCTs are sparse. We can’t point to a multi-lab replication story the way we can for something like ipamorelin or BPC-157. The WADA ban is indirect evidence of real biological effect, but that’s a thin reed for a research program.

Honestly, bromantane slots in as a mechanistically distinctive but evidence-limited compound. We think researchers interested in dopamine synthesis biology or in the pharmacology of stress adaptation without stimulant side effects will find it worth cataloguing. But it’s not something you’d build a primary research program around without first sorting out the translational evidence gap. The mechanism promise is real; the replication story isn’t there yet.

Novelty: 38
Mechanism promise: 58
In-category differentiation: 57
Evidence quality: 38
Translational signal: 42
Research bench value: 42

Rationale Bromantane’s core interest lies in its mechanistic combination: dopamine synthesis upregulation (not release, not transporter inhibition) paired with non-GABAergic anxiolysis. That dual profile is genuinely differentiated. The drag is evidence quality: the clinical literature is substantial but almost entirely Russian-language, which makes independent verification difficult and keeps evidence and translational scores well below what a Western-replicated program would earn.

Adamantane-derived adaptogen

A Soviet-developed adamantane derivative (Ladasten) approved in Russia for asthenia with mixed psychostimulant and anxiolytic effects.

Abstract

Bromantane (Ladasten; ADK-709; N-(2-adamantyl)-N-(p-bromophenyl)amine; CAS 87913-26-6; molecular formula C16H20BrN; molecular weight 306.24) is an adamantane derivative developed in the Soviet Union in the 1980s, originally for military applications (combat fatigue, cold tolerance). The compound is approved in Russia as Ladasten for asthenia and neurasthenia. Pharmacology is distinctive: bromantane combines mild dopaminergic activation (through enhanced dopamine synthesis rather than transporter inhibition or release) with anxiolytic effects through a non-GABAergic mechanism. The combination produces a clinical profile described as “actoprotective” . improving physical and mental performance under stress without the rebound fatigue typical of stimulants or the sedation typical of anxiolytics. Bromantane is on the WADA prohibited list (banned in 1996). Pharmacokinetics: plasma half-life 9 to 12 hours; oral bioavailability good. Doses are 50 to 100 mg per day. Russian clinical literature is substantial; English-language randomized trials are limited.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-063Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: KDC-MN-063

Bromantane

Abstract

Read the full monograph